Previous Article | Next Article 
Journal of Virology, May 2004, p. 4710-4719, Vol. 78, No. 9
0022-538X/04/$08.00+0 DOI: 10.1128/JVI.78.9.4710-4719.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Elicitation of Neutralizing Antibodies with DNA Vaccines Expressing Soluble Stabilized Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers Conjugated to C3d
Joseph F. Bower,1 Xinzhen Yang,2 Joseph Sodroski,2 and Ted M. Ross1*
Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania,1
Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, and Division of AIDS, Harvard Medical School, Boston, Massachusetts2
Received 12 August 2003/
Accepted 24 December 2003
DNA vaccines expressing the envelope (Env) of human immunodeficiency virus type 1 (HIV-1) have been relatively ineffective at generating high-titer, long-lasting immune responses. Oligomeric or trimeric (gp140) forms of Env that more closely mimic the native proteins on the virion are often more effective immunogens than monomeric (gp120) envelopes. In this study, several forms of Env constructed from the HIV-1 isolate YU-2 (HIV-1YU-2) were tested for their immunogenic potential: a trimeric form of uncleaved () Env stabilized with a synthetic trimer motif isolated from the fibritin (FT) protein of the T4 bacteriophage, sgp140YU-2(/FT), was compared to sgp140YU-2() without a synthetic trimerization domain, as well as to monomeric gp120YU-2. DNA plasmids were constructed to express Env alone or fused to various copies of murine C3d (mC3d). BALB/c mice were vaccinated (day 1 and week 4) with DNA expressing a codon-optimized envelope gene insert, alone or fused to mC3d. Mice were subsequently boosted (week 8) with the DNA or recombinant Env protein. All mice had high anti-Env antibody titers regardless of the use of mC3d. Sera from mice vaccinated with DNA expressing non-C3d-fused trimers elicited neutralizing antibodies against homologous HIV-1YU-2 virus infection in vitro. In contrast, sera from mice inoculated with DNA expressing Env-C3d protein trimers elicited antibody that neutralized both homologous HIV-1YU-2 and heterologous HIV-1ADA, albeit at low titers. Therefore, DNA vaccines expressing trimeric envelopes coupled to mC3d, expressed in vivo from codon-optimized sequences, elicit low titers of neutralizing antibodies against primary isolates of HIV-1.
* Corresponding author. Mailing address: Division of Infectious Diseases, Department of Medicine, School of Medicine, University of Pittsburgh, Scaife Hall, Suite 871, 3550 Terrace St., Pittsburgh, PA 15261. Phone: (412) 648-8666. Fax: (412) 648-8455. E-mail:
RossT{at}msx.dept-med.pitt.edu.
Journal of Virology, May 2004, p. 4710-4719, Vol. 78, No. 9
0022-538X/04/$08.00+0 DOI: 10.1128/JVI.78.9.4710-4719.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Dosenovic, P., Chakrabarti, B., Soldemo, M., Douagi, I., Forsell, M. N. E., Li, Y., Phogat, A., Paulie, S., Hoxie, J., Wyatt, R. T., Karlsson Hedestam, G. B.
(2009). Selective Expansion of HIV-1 Envelope Glycoprotein-Specific B Cell Subsets Recognizing Distinct Structural Elements Following Immunization. J. Immunol.
183: 3373-3382
[Abstract]
[Full Text]
-
Morner, A., Douagi, I., Forsell, M. N. E., Sundling, C., Dosenovic, P., O'Dell, S., Dey, B., Kwong, P. D., Voss, G., Thorstensson, R., Mascola, J. R., Wyatt, R. T., Karlsson Hedestam, G. B.
(2009). Human Immunodeficiency Virus Type 1 Env Trimer Immunization of Macaques and Impact of Priming with Viral Vector or Stabilized Core Protein. J. Virol.
83: 540-551
[Abstract]
[Full Text]
-
Jegou, J.-F., Chan, P., Schouft, M.-T., Griffiths, M. R., Neal, J. W., Gasque, P., Vaudry, H., Fontaine, M.
(2007). C3d Binding to the Myelin Oligodendrocyte Glycoprotein Results in an Exacerbated Experimental Autoimmune Encephalomyelitis. J. Immunol.
178: 3323-3331
[Abstract]
[Full Text]
-
Derby, N. R., Kraft, Z., Kan, E., Crooks, E. T., Barnett, S. W., Srivastava, I. K., Binley, J. M., Stamatatos, L.
(2006). Antibody Responses Elicited in Macaques Immunized with Human Immunodeficiency Virus Type 1 (HIV-1) SF162-Derived gp140 Envelope Immunogens: Comparison with Those Elicited during Homologous Simian/Human Immunodeficiency Virus SHIVSF162P4 and Heterologous HIV-1 Infection.. J. Virol.
80: 8745-8762
[Abstract]
[Full Text]
-
Selvarajah, S., Puffer, B., Pantophlet, R., Law, M., Doms, R. W., Burton, D. R.
(2005). Comparing Antigenicity and Immunogenicity of Engineered gp120. J. Virol.
79: 12148-12163
[Abstract]
[Full Text]
-
Beddows, S., Schulke, N., Kirschner, M., Barnes, K., Franti, M., Michael, E., Ketas, T., Sanders, R. W., Maddon, P. J., Olson, W. C., Moore, J. P.
(2005). Evaluating the Immunogenicity of a Disulfide-Stabilized, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1. J. Virol.
79: 8812-8827
[Abstract]
[Full Text]
-
Ichinohe, T., Watanabe, I., Ito, S., Fujii, H., Moriyama, M., Tamura, S.-i., Takahashi, H., Sawa, H., Chiba, J., Kurata, T., Sata, T., Hasegawa, H.
(2005). Synthetic Double-Stranded RNA Poly(I:C) Combined with Mucosal Vaccine Protects against Influenza Virus Infection. J. Virol.
79: 2910-2919
[Abstract]
[Full Text]
-
Gorantla, S., Santos, K., Meyer, V., Dewhurst, S., Bowers, W. J., Federoff, H. J., Gendelman, H. E., Poluektova, L.
(2005). Human Dendritic Cells Transduced with Herpes Simplex Virus Amplicons Encoding Human Immunodeficiency Virus Type 1 (HIV-1) gp120 Elicit Adaptive Immune Responses from Human Cells Engrafted into NOD/SCID Mice and Confer Partial Protection against HIV-1 Challenge. J. Virol.
79: 2124-2132
[Abstract]
[Full Text]
-
Varadarajan, R., Sharma, D., Chakraborty, K., Patel, M., Citron, M., Sinha, P., Yadav, R., Rashid, U., Kennedy, S., Eckert, D., Geleziunas, R., Bramhill, D., Schleif, W., Liang, X., Shiver, J.
(2005). Characterization of gp120 and Its Single-Chain Derivatives, gp120-CD4D12 and gp120-M9: Implications for Targeting the CD4i Epitope in Human Immunodeficiency Virus Vaccine Design. J. Virol.
79: 1713-1723
[Abstract]
[Full Text]